Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study



Status:Completed
Conditions:Cancer, Vaccines, Infectious Disease, Women's Studies
Therapuetic Areas:Immunology / Infectious Diseases, Oncology, Reproductive
Healthy:No
Age Range:26 - Any
Updated:12/19/2018
Start Date:April 1, 2011
End Date:November 23, 2017

Use our guide to learn which trials are right for you!

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study

This extension study is designed to assess the safety of GSK Biological's human
papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study
NCT00294047 and received the control vaccine in countries for which the licensed GSK HPV
vaccine is not indicated for the subject's age group (26 years and older). This study is thus
conducted to enable all women who received the control placebo in the primary NCT00294047
study to receive the GSK580299 vaccine.

This Protocol Posting has been updated following Protocol Amendment 1, December 2010, leading
to the update of 1 of the primary outcome measures and following Protocol Amendment 2,
January 2011, leading to the removal of one of the exclusion criteria.

Inclusion Criteria:

- Subjects who the investigator believes can and will comply with the requirements of
the protocol

- A subject previously enrolled in study NCT00294047, who received the control vaccine,
and who cannot receive the GSK580299 vaccine because the subject is above the age for
which the vaccine is licensed.

- Written informed consent obtained from the subject

- Free of obvious health problems as established by medical history and clinical
examination before entering into the study.

- Female subjects of non-childbearing potential may be enrolled in the study.

- Female subjects of childbearing potential may be enrolled in the study, if the
subject:

- has practiced adequate contraception for 30 days prior to vaccination, and

- has a negative pregnancy test on the day of vaccination, and

- has agreed to continue adequate contraception during the entire treatment period
and for 2 months after completion of the vaccination series.

Exclusion Criteria:

- Pregnant or breastfeeding.

- A women planning to become pregnant, likely to become pregnant or planning to
discontinue contraceptive precautions during the vaccination phase of the study, i.e.
up to two months after the last vaccine dose.

- Use of any investigational or non-registered product other than the study vaccine
within 30 days preceding the first dose of study vaccine, or planned use during the
study period.

- Previous vaccination against HPV or planned administration of another HPV vaccine
during the study other than that foreseen in the protocol.

- Chronic administration of immunosuppressants or other immune-modifying drugs within
six months prior to the first vaccine dose. For corticosteroids, this will mean
prednisone greater than or equal to 20 mg/day, or equivalent. Inhaled and topical
steroids are allowed

- Planned administration/administration of a vaccine not foreseen by the study protocol
within 30 days (i.e., Day 0-29) of each dose of vaccine, with the exception of
administration of routine meningococcal, hepatitis B, hepatitis A, inactivated
influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccine up to 8
days before each dose of study vaccine. Enrolment will be deferred until the subject
is outside of specified window.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product.

NOTE: Subjects enrolled in this study may also be eligible for a four-year gynaecological
follow-up of the HPV-015 study, in which no investigational product will be administered.
Subjects will be invited to the gynaecological follow-up study if either of the following
applies:

- if they test positive for oncogenic HPV infection, but display normal cervical
cytology at their concluding HPV-015 study end visit;

- if they are pregnant so that no cervical sample can be taken at their concluding
HPV-015 study end visit;

- Previous administration of any components of the vaccine.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based
on medical history and physical examination.

- Cancer or autoimmune disease under treatment.

- Administration of immunoglobulins and/or any blood products within the 3 months
preceding the first dose of study vaccine or planned administration during the
study period.

- History of any reaction or hypersensitivity likely to be exacerbated by any
component of the vaccine

- History of any neurological disorders or seizures.

- Acute disease and/or fever at the time of enrolment.

- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or
renal functional abnormality, as determined by physical examination or laboratory
screening tests.
We found this trial at
24
sites
Salt Lake City, Utah 84132
Phone: 877-379-3718
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Augusta, Georgia 30909
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80010
Phone: 877-379-3718
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bardstown, Kentucky 40004
Phone: 877-379-3718
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Carnegie, Pennsylvania 15106
Phone: 877-379-3718
?
mi
from
Carnegie, PA
Click here to add this to my saved trials
Cleveland, Ohio 44195
Phone: 877-379-3718
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Coral Gables, Florida 33134
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Edmonton, Alberta
Phone: 877-379-3718
?
mi
from
Edmonton,
Click here to add this to my saved trials
Erie, Pennsylvania 16507
Phone: 877-379-3718
?
mi
from
Erie, PA
Click here to add this to my saved trials
Erie, Pennsylvania 16507
?
mi
from
Erie, PA
Click here to add this to my saved trials
Golden, Colorado 80401
Phone: 877-379-3718
?
mi
from
Golden, CO
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 877-379-3718
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
Phone: 877-379-3718
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
La Crosse, Wisconsin 54601
?
mi
from
La Crosse, WI
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
Phone: 877-379-3718
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Louisville, Kentucky 40202
Phone: 877-379-3718
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami, Florida 33136
Phone: 877-379-3718
?
mi
from
Miami, FL
Click here to add this to my saved trials
New Bern, North Carolina 28562
Phone: 877-379-3718
?
mi
from
New Bern, NC
Click here to add this to my saved trials
Omaha, Nebraska 68131
Phone: 877-379-3718
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Phone: 877-379-3718
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
South Jordan, Utah 84095
?
mi
from
South Jordan, UT
Click here to add this to my saved trials
Wenatchee, Washington 98801
Phone: 877-379-3718
?
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Wichita, Kansas 67207
Phone: 877-379-3718
?
mi
from
Wichita, KS
Click here to add this to my saved trials